Zhigang Han
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhigang Han has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Chee Khoon Lee
NHMRC Clinical Trials Centre, The University of Sydney, Sydney, Australia
3 shared publications - Frances A. Shepherd
Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
3 shared publications - Gustavo Dix Junqueira Pinto
Hospital de Câncer de Barretos 11 Barretos
3 shared publications - Jerry Tan Chun Bing
Cebu Doctors' University 9 Cebu City
3 shared publications - Jhanelle Elaine Gray
Department of Thoracic Oncology, Moffitt Cancer Center, Tampa, FL 33612, USA
3 shared publications - Jialei Wang
Department of Thoracic Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China
3 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Supplementary Table S1. Representativeness of study participants Supplementary Table S2. Averagea change from baseline in prespecified key EORTC QLQ-C30 and QLQ-LC13 scale scores over all timepoints (MMRM). Supplementary Figure S1. Patient-reported outcome assessment schedules in FLAURA2. Supplementary Figure S2. Patient-reported outcome questionnaire compliance rates. Supplementary Figure S3. Proportion of patients with different A, frequency and B, severity scores for the additional prespecified PRO-CTCAE symptoms at different timepoints. Weeks 13 (3.0 months), 37 (8.5 months), and 97 (22.3 months) of the PRO-CTCAE assessments represent the closest available timepoints to the end of the induction, median pemetrexed maintenance and median osimertinib treatment, respectively, for the osimertinib plus chemotherapy arm. Conditional branching logic was employed for PRO-CTCAE symptom terms that have two or more attributes, thereby reducing the sample size from frequency to severity for symptoms. PRO-CTCAE, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose:In FLAURA2, first-line osimertinib plus platinum–pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non–small cell lung cancer (NSCLC; hazard ratio, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PRO).Patients and Methods:Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (baseline, week 4, week 7, week 10, then every 6 weeks until progression) and QLQ Lung Cancer 13 (baseline, weekly until week 10, then every 3 weeks until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-Common Terminology Criteria for Adverse Events (CTCAE).Results:Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomatology (≤35). Most key scales showed nonclinically meaningful improvements; average least-squares mean (LSM) changes [95% confidence interval (CI)] for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination therapy and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination therapy and monotherapy from week 5 (except monotherapy at week 73); average LSM changes (95% CI) were −13.23 (−14.85 to −11.62) and −11.19 (−12.83 to −9.55), respectively. Nonclinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE).Conclusions:In FLAURA2, osimertinib monotherapy and combination with platinum–pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had nonclinically meaningful impacts on HRQoL in mildly symptomatic patients.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose:In FLAURA2, first-line osimertinib plus platinum–pemetrexed induction, with osimertinib plus pemetrexed maintenance, improved progression-free survival versus osimertinib alone in epidermal growth factor receptor (EGFR)-mutated, advanced non–small cell lung cancer (NSCLC; hazard ratio, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PRO).Patients and Methods:Health-related quality of life (HRQoL) was measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (QLQ) Core 30 (baseline, week 4, week 7, week 10, then every 6 weeks until progression) and QLQ Lung Cancer 13 (baseline, weekly until week 10, then every 3 weeks until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-Common Terminology Criteria for Adverse Events (CTCAE).Results:Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomatology (≤35). Most key scales showed nonclinically meaningful improvements; average least-squares mean (LSM) changes [95% confidence interval (CI)] for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination therapy and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination therapy and monotherapy from week 5 (except monotherapy at week 73); average LSM changes (95% CI) were −13.23 (−14.85 to −11.62) and −11.19 (−12.83 to −9.55), respectively. Nonclinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE).Conclusions:In FLAURA2, osimertinib monotherapy and combination with platinum–pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had nonclinically meaningful impacts on HRQoL in mildly symptomatic patients.
- Open Access
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2144-2156
Patient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance improved progression-free survival versus osimertinib alone in EGFR-mutated, advanced non–small cell lung cancer (NSCLC) (HR, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PROs). Patients and Methods: Health-related quality of life (HRQoL) was measured using EORTC QLQ-C30 (baseline, Week [W] 4, W7, W10, then 6-weekly until progression) and QLQ-LC13 (baseline, weekly until W10, then 3-weekly until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-CTCAE. Results: Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomology (≤35). Most key scales showed non-clinically meaningful improvements; average least-squares mean [LSM] changes (95% CI) for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination and monotherapy from W5 (except monotherapy at W73); average LSM change (95% CI) -13.23 (-14.85 – -11.62) and -11.19 (-12.83 – -9.55), respectively. Non-clinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE). Conclusions: In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.
- 9 March 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (11) , 2144-2156
Open AccessPatient-Reported Outcomes in FLAURA2: Osimertinib with or without Chemotherapy in Patients with Previously Untreated EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Purpose: In FLAURA2, first-line osimertinib plus platinum-pemetrexed induction, with osimertinib plus pemetrexed maintenance improved progression-free survival versus osimertinib alone in EGFR-mutated, advanced non–small cell lung cancer (NSCLC) (HR, 0.62; P < 0.001). Combining osimertinib with chemotherapy increased induction grade ≥3 adverse event rates, which reduced during maintenance. We report FLAURA2 patient-reported outcomes (PROs). Patients and Methods: Health-related quality of life (HRQoL) was measured using EORTC QLQ-C30 (baseline, Week [W] 4, W7, W10, then 6-weekly until progression) and QLQ-LC13 (baseline, weekly until W10, then 3-weekly until progression). Score changes (baseline to progression/19 months) were analyzed by mixed models for repeated measures. Within-patient ≥10-point changes from baseline were considered clinically meaningful. Tolerability was assessed by PRO-CTCAE. Results: Patients had intermediate-to-high baseline functioning and global health status (GHS)/QoL (mean scores ≥63), with mild symptomology (≤35). Most key scales showed non-clinically meaningful improvements; average least-squares mean [LSM] changes (95% CI) for GHS/QoL and physical function, respectively, were 3.32 (1.67–4.98) and 2.37 (0.70–4.04) with combination and 7.38 (5.70–9.07) and 6.74 (5.04–8.43) with monotherapy. Improvements in cough were clinically meaningful with combination and monotherapy from W5 (except monotherapy at W73); average LSM change (95% CI) -13.23 (-14.85 – -11.62) and -11.19 (-12.83 – -9.55), respectively. Non-clinically meaningful deteriorations in fatigue and appetite loss were seen with the combination during induction. Both treatments were similarly well tolerated (PRO-CTCAE). Conclusions: In FLAURA2, osimertinib monotherapy and combination with platinum-pemetrexed as first-line treatment for EGFR-mutated advanced NSCLC had non-clinically meaningful impacts on HRQoL in mildly symptomatic patients.